Treatment options for pemphigus foliaceus

Area of Science:

• Dermatology
• Autoimmune Diseases
• Immunology

Background:

• Pemphigus foliaceus is a rare autoimmune blistering disease.
• Corticosteroids reduce mortality but have adverse events.
• Steroid-sparing agents also have serious side effects with limited trial data.

Purpose of the Study:

• To review current and emerging therapies for pemphigus foliaceus.
• To assess the efficacy and safety of different treatment modalities.
• To identify areas for future research in pemphigus foliaceus management.

Main Methods:

• Literature review of current treatment strategies.
• Analysis of randomized controlled trials and case series.
• Evaluation of novel therapeutic agents and their reported outcomes.

Main Results:

• Azathioprine and mycophenolate mofetil are feasible first-line adjunctive agents for remission induction and maintenance.
• Novel therapies like biologics and rituximab show potential but have limitations.
• Rituximab is emerging as a treatment of choice for severe refractory pemphigus foliaceus.

Conclusions:

• Current treatments for pemphigus foliaceus involve corticosteroids and steroid-sparing agents with significant side effects.
• Emerging therapies offer new hope but require further investigation regarding efficacy and safety.
• Future research should focus on targeted therapies like peptide immunotherapy and intracellular signaling modulators.